PRESS RELEASES

Date Title and Summary View
Toggle Summary Galectin Therapeutics Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation NORCROSS, Ga., Feb. 6, 2017 /CNW/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the February 2nd presenta...
View HTML
Toggle Summary Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial
NORCROSS, Ga., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated sufficient financing to cover currently planned expenditures through 2017 and it remains on track to present top line data from its NASH-CX Phase 2 clinica...
View HTML
Toggle Summary Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2
The Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com NORCROSS, Ga., Jan. 30, 2017 /CNW/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Trabe...
View HTML
Toggle Summary Galectin Therapeutics Announces $4 Million in New Equity Financings
NORCROSS, Ga., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has recently completed  a private placement of its common stock, raising $3,000,000 in new funding.  In a separate transaction, the Company also closed an additional sal...
View HTML
Toggle Summary Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders
NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company will present a corporate update via live webcast immediately following the business portion of its 2016
View HTML
Toggle Summary Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases
Meaningful activity of GR-MD-02 in treating psoriasis and preliminary data in treating atopic dermatitis suggests promise in treatment of serious skin disease
View HTML
Toggle Summary Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update
NORCROSS, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three and nine months ended September 30, 2016.
View HTML
Toggle Summary Galectin Therapeutics to Webcast Corporate Presentation at the MicroCap Conference on October 25 in Philadelphia
NORCROSS, Ga., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the company's president, chief executive officer and chief medical
View HTML
Toggle Summary Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis
Research to be presented at The Liver Meeting® 2016 demonstrates correlation of FibroScan and MRE as non-invasive tests to assess the progression of liver fibrosis and cirrhosis
View HTML
Toggle Summary Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis
Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled Closed private placement financing for $1.5 million Conference call to be held today at 5:30 p.m. (Eastern Time) NORCOSS, Ga., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
View HTML